Literature DB >> 15842561

Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1).

Mikko Niemi, Kari T Kivistö, Ute Hofmann, Matthias Schwab, Michel Eichelbaum, Martin F Fromm.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15842561      PMCID： PMC1884844          DOI： 10.1111/j.1365-2125.2005.02354.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  15 in total

Review 1.  Pharmacogenomics of the OATP and OAT families.

Authors:  Catia Marzolini; Rommel G Tirona; Richard B Kim
Journal:  Pharmacogenomics       Date:  2004-04       Impact factor: 2.533

2.  Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine.

Authors:  George K Dresser; David G Bailey; Brenda F Leake; Ute I Schwarz; Paul A Dawson; David J Freeman; Richard B Kim
Journal:  Clin Pharmacol Ther       Date:  2002-01       Impact factor: 6.875

3.  Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family.

Authors:  I Tamai; J Nezu; H Uchino; Y Sai; A Oku; M Shimane; A Tsuji
Journal:  Biochem Biophys Res Commun       Date:  2000-06-24       Impact factor: 3.575

4.  Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans.

Authors:  R G Tirona; B F Leake; G Merino; R B Kim
Journal:  J Biol Chem       Date:  2001-07-26       Impact factor: 5.157

Review 5.  Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events.

Authors:  T Hatanaka
Journal:  Clin Pharmacokinet       Date:  2000-12       Impact factor: 6.447

6.  OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine.

Authors:  M Cvetkovic; B Leake; M F Fromm; G R Wilkinson; R B Kim
Journal:  Drug Metab Dispos       Date:  1999-08       Impact factor: 3.922

7.  MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine.

Authors:  Siegfried Drescher; Elke Schaeffeler; Monika Hitzl; Ute Hofmann; Matthias Schwab; Ulrich Brinkmann; Michel Eichelbaum; Martin F Fromm
Journal:  Br J Clin Pharmacol       Date:  2002-05       Impact factor: 4.335

8.  Identification of functionally variant MDR1 alleles among European Americans and African Americans.

Authors:  R B Kim; B F Leake; E F Choo; G K Dresser; S V Kubba; U I Schwarz; A Taylor; H G Xie; J McKinsey; S Zhou; L B Lan; J D Schuetz; E G Schuetz; G R Wilkinson
Journal:  Clin Pharmacol Ther       Date:  2001-08       Impact factor: 6.875

9.  High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1).

Authors:  Mikko Niemi; Elke Schaeffeler; Thomas Lang; Martin F Fromm; Mikko Neuvonen; Carl Kyrklund; Janne T Backman; Reinhold Kerb; Matthias Schwab; Pertti J Neuvonen; Michel Eichelbaum; Kari T Kivistö
Journal:  Pharmacogenetics       Date:  2004-07

Review 10.  Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance.

Authors:  Catia Marzolini; Erik Paus; Thierry Buclin; Richard B Kim
Journal:  Clin Pharmacol Ther       Date:  2004-01       Impact factor: 6.875
View more
  36 in total

1.  Frequency of the SLCO1B1 388A>G and the 521T>C polymorphism in Tanzania genotyped by a new LightCycler®-based method.

Authors:  Eleni Aklillu; Sabina Mugusi; Eliford Ngaimisi; Michael Marcus Hoffmann; Sonja König; Victoria Ziesenitz; Gerd Mikus; Walter Emil Haefeli; Johanna Weiss
Journal:  Eur J Clin Pharmacol       Date:  2011-06-01       Impact factor: 2.953

2.  Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition.

Authors:  Laura B Ramsey; Gitte H Bruun; Wenjian Yang; Lisa R Treviño; Selina Vattathil; Paul Scheet; Cheng Cheng; Gary L Rosner; Kathleen M Giacomini; Yiping Fan; Alex Sparreboom; Torben S Mikkelsen; Thomas J Corydon; Ching-Hon Pui; William E Evans; Mary V Relling
Journal:  Genome Res       Date:  2011-12-06       Impact factor: 9.043

3.  Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population.

Authors:  Marja K Pasanen; Janne T Backman; Pertti J Neuvonen; Mikko Niemi
Journal:  Eur J Clin Pharmacol       Date:  2006-04-21       Impact factor: 2.953

4.  Effects of single and multiple doses of itraconazole on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein.

Authors:  Mikiko Shimizu; Tsukasa Uno; Kazunobu Sugawara; Tomonori Tateishi
Journal:  Br J Clin Pharmacol       Date:  2006-06-23       Impact factor: 4.335

Review 5.  Drug transporters in pharmacokinetics.

Authors:  Ernst Petzinger; Joachim Geyer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-03-11       Impact factor: 3.000

Review 6.  Pharmacogenomics of human OATP transporters.

Authors:  Jörg König; Annick Seithel; Ulrike Gradhand; Martin F Fromm
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-03-09       Impact factor: 3.000

7.  Integration of preclinical and clinical data with pharmacokinetic modeling and simulation to evaluate fexofenadine as a probe for hepatobiliary transport function.

Authors:  Brandon Swift; Xianbin Tian; Kim L R Brouwer
Journal:  Pharm Res       Date:  2009-06-04       Impact factor: 4.200

8.  Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities.

Authors:  E D Kharasch; P S Bedynek; A Walker; D Whittington; C Hoffer
Journal:  Clin Pharmacol Ther       Date:  2008-10       Impact factor: 6.875

9.  Non-synonymous polymorphisms in the human SLCO1B1 gene: an in vitro analysis of SNP c.1929A>C.

Authors:  Annick Seithel; Kathrin Klein; Ulrich M Zanger; Martin F Fromm; Jörg König
Journal:  Mol Genet Genomics       Date:  2007-11-08       Impact factor: 3.291

10.  PharmGKB very important pharmacogene: SLCO1B1.

Authors:  Connie Oshiro; Lara Mangravite; Teri Klein; Russ Altman
Journal:  Pharmacogenet Genomics       Date:  2010-03       Impact factor: 2.089
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.